CC
KYMR icon

Commodore Capital’s Kymera Therapeutics KYMR Stock Holding History

Commodore Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.5M Hold
750,000
– – 3.61% 10
2025
Q4 		$58.4M Hold
750,000
– – 3.88% 11
2025
Q3 		$42.5M Hold
750,000
– – 2.07% 19
2025
Q2 		$32.7M Buy
+750,000
New +$25.8M 2.31% 17

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Commodore Capital's KYMR Position: Q1 2026 in Review

Commodore Capital held its Kymera Therapeutics (KYMR) position steady in Q1 2026 at 750,000 shares worth $62.5M. The position accounts for 3.61% of the portfolio, ranked #10.

Commodore Capital first reported a position in KYMR in Q2 2025 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Commodore Capital held 750,000 shares of Kymera Therapeutics worth $62.5M as of Q1 2026.
  • Commodore Capital left its Kymera Therapeutics share count unchanged in Q1 2026.
  • Kymera Therapeutics made up 3.61% of Commodore Capital's portfolio in Q1 2026, its #10 holding.
  • Commodore Capital first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.